Success Metrics

Clinical Success Rate
33.3%

Based on 2 completed trials

Completion Rate
33%(2/6)
Active Trials
1(9%)
Results Posted
150%(3 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_1
2
18%
Ph phase_3
1
9%
Ph phase_2
8
73%

Phase Distribution

2

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
8(72.7%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(2)
Terminated(5)
Other(3)

Detailed Status

Terminated4
unknown3
Completed2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 28 (72.7%)
Phase 31 (9.1%)

Trials by Status

unknown327%
active_not_recruiting19%
terminated436%
completed218%
withdrawn19%

Recent Activity

1 active trials
Showing 5 of 11
terminatedphase_3

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

NCT04797780
active_not_recruitingphase_2

Study of Tamibarotene in Patients With ADPKD

NCT06289998
terminatedphase_2

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT04905407
completedphase_2

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558
withdrawnphase_1

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

NCT06085638
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04797780Phase 3

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
NCT06289998Phase 2

Study of Tamibarotene in Patients With ADPKD

Active Not Recruiting
NCT04905407Phase 2

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated
NCT02807558Phase 2

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed
NCT06085638Phase 1

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Withdrawn
NCT00985530Phase 1

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Terminated
NCT01337154Phase 2

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Terminated
NCT00520208Phase 2

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

Completed
NCT01226147Phase 2

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

Unknown
NCT01120002Phase 2

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

Unknown
NCT01343355Phase 2

Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11